Page 159 - Haematologica March 2020

Bone marrow niche dysfunction in ET
Acute myelogenous leukemia-induced sympathetic neuropathy promotes malig- nancy in an altered hematopoietic stem cell niche. Cell Stem Cell. 2014;15(3):365-375.
10. Hanoun M, Maryanovich M, Arnal-Estape A, Frenette PS. Neural regulation of hematopoiesis, inflammation, and cancer. Neuron. 2015;86(2):360-373.
11. Maestroni GJM. Adrenergic modulation of haematopoiesis. J. Neuroimmune. Pharmacol. 2019 Feb 14. [Epub ahead of print].
12. Pavlov VA, Chavan SS, Tracey KJ. Molecular and functional neuroscience in immunity. Annu Rev Immunol. 2018; 36:783-812.
13. Broxmeyer HE, Bruns HA, Zhang S, et al. Th1 cells regulate hematopoietic progeni- tor cell homeostasis by production of onco- statin M. Immunity. 2002;16(6):815-825.
14. Gao A, Gong Y, Zhu C, et al. Bone marrow endothelial cell-derived interleukin-4 con- tributes to thrombocytopenia in acute myeloid leukemia. Haematologica. 2019 Feb 21. [Epub ahead of print].
15. Keller U, Aman MJ, Derigs G, Huber C, Peschel C. Human interleukin-4 enhances stromal cell-dependent hematopoiesis: cos- timulation with stem cell factor. Blood. 1994;84(7):2189-2196.
16. Agarwala S, Tamplin OJ. Neural crossroads in the hematopoietic stem cell niche. Trends Cell Biol. 2018;28(12):987-998.
17. Tripodo C, Burocchi A, Piccaluga PP, et al. Persistent immune stimulation exacerbates genetically driven myeloproliferative disor- ders via stromal remodeling. Cancer Res. 2017;77(13):3685-3699.
18. Buttner R, Schulz A, Reuter M, et al. Inflammaging impairs peripheral nerve maintenance and regeneration. Aging Cell. 2018;17(6):e12833.
19. Arranz L, Sanchez-Aguilera A, Martin- Perez D, et al. Neuropathy of haematopoi- etic stem cell niche is essential for myelo- proliferative neoplasms. Nature. 2014;512(7512):78-81.
20. Jones SA, Jenkins BJ. Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. Nat Rev Immunol. 2018;18(12):773-789.
21. Verboogen DRJ, Revelo NH, Ter Beest M, van den Bogaart G. Interleukin-6 secretion is limited by self-signaling in endosomes. J Mol Cell Biol. 2019;11(2):144-157.
22. Csaszar E, Wang W, Usenko T, et al. Blood stem cell fate regulation by Delta-1-mediat- ed rewiring of IL-6 paracrine signaling. Blood. 2014;123(5):650-658.
23. Jiang C, Zhang Q, Shanti RM, et al. Mesenchymal stromal cell-derived inter- leukin-6 promotes epithelial-mesenchymal transition and acquisition of epithelial stem-like cell properties in ameloblastoma epithelial cells. Stem Cells. 2017;35(9):2083-2094.
24. Jenkins BJ, Roberts AW, Najdovska M, Grail D, Ernst M. The threshold of gp130- dependent STAT3 signaling is critical for normal regulation of hematopoiesis. Blood.
2005;105(9):3512-3520.
25. Jenkins BJ, Roberts AW, Greenhill CJ, et al.
Pathologic consequences of STAT3 hyper- activation by IL-6 and IL-11 during hematopoiesis and lymphopoiesis. Blood. 2007;109(6):2380-2388.
26. Chiba Y, Mizoguchi I, Hasegawa H, et al. Regulation of myelopoiesis by proinflam- matory cytokines in infectious diseases. Cell Mol Life Sci. 2018;75(8):1363-1376.
27. Maeda K, Mehta H, Drevets DA, Coggeshall KM. IL-6 increases B-cell IgG production in a feed-forward proinflamma- tory mechanism to skew hematopoiesis and elevate myeloid production. Blood. 2010;115(23):4699-4706.
28. LiR,XinT,LiD,WangC,ZhuH,ZhouH. Therapeutic effect of Sirtuin 3 on amelio- rating nonalcoholic fatty liver disease: The role of the ERK-CREB pathway and Bnip3- mediated mitophagy. Redox Biol. 2018; 18:229-243.
29. Rodionova E, Conzelmann M, Maraskovsky E, et al. GSK-3 mediates dif- ferentiation and activation of proinflamma- tory dendritic cells. Blood. 2007; 109(4):1584-1592.
30. Yun MR, Choi HM, Kang HN, et al. ERK- dependent IL-6 autocrine signaling medi- ates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squa- mous cell carcinoma. Oncogene. 2018;37(3):377-388.
31. Lin S, Liu Q, Lelyveld VS, Choe J, Szostak JW, Gregory RI. Mettl1/Wdr4-mediated m(7)G tRNA methylome is required for normal mRNA translation and embryonic stem cell self-renewal and differentiation. Mol Cell. 2018;71(2):244-255.e5.
32. Schapira M, Tyers M, Torrent M, Arrowsmith CH. WD40 repeat domain proteins: a novel target class? Nat Rev Drug Discov. 2017;16(11):773-786.
33. Wang YT, Chen J, Chang CW, et al. Ubiquitination of tumor suppressor PML regulates prometastatic and immunosup- pressive tumor microenvironment. J Clin Invest. 2017;127(8):2982-2997.
34. Avanzini MA, Bernardo ME, Novara F, et al. Functional and genetic aberrations of in vitro-cultured marrow-derived mesenchy- mal stromal cells of patients with classical Philadelphia-negative myeloproliferative neoplasms. Leukemia. 2014;28(8):1742- 1745.
35. Greenbaum A, Hsu YM, Day RB, et al. CXCL12 in early mesenchymal progenitors is required for haematopoietic stem-cell maintenance. Nature. 2013;495(7440):227- 230.
36. Flores-Figueroa E, Varma S, Montgomery K, Greenberg PL, Gratzinger D. Distinctive contact between CD34+ hematopoietic progenitors and CXCL12+ CD271+ mes- enchymal stromal cells in benign and myelodysplastic bone marrow. Lab Invest. 2012;92(9):1330-1341.
37. Hock H, Hamblen MJ, Rooke HM, et al. Gfi-1 restricts proliferation and preserves functional integrity of haematopoietic stem
cells. Nature. 2004;431(7011):1002-1007. 38. Moravcikova E, Meyer EM, Corselli M, Donnenberg VS, Donnenberg AD. Proteomic profiling of native unpassaged and culture-expanded mesenchymal stro- mal cells (MSC). Cytometry A.
2018;93(9):894-904.
39. Lacout C, Pisani DF, Tulliez M, Gachelin
FM, Vainchenker W, Villeval JL. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood. 2006;108(5):1652-1660.
40. Akada H, Yan D, Zou H, Fiering S, Hutchison RE, Mohi MG. Conditional expression of heterozygous or homozy- gous Jak2V617F from its endogenous pro- moter induces a polycythemia vera-like disease. Blood. 2010;115(17):3589-3597.
41. Tiedt R, Hao-Shen H, Sobas MA, et al. Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood. 2008;111(8):3931- 3940.
42. Pinto AI, Brown N, Preham O, Doehl JSP, Ashwin H, Kaye PM. TNF signalling drives expansion of bone marrow CD4+ T cells responsible for HSC exhaustion in experi- mental visceral leishmaniasis. PLoS Pathog. 2017;13(7):e1006465.
43. Nemeth K, Keane-Myers A, Brown JM, et al. Bone marrow stromal cells use TGF-beta to suppress allergic responses in a mouse model of ragweed-induced asthma. Proc Natl Acad Sci USA. 2010;107(12):5652- 5657.
44. Mounayar M, Kefaloyianni E, Smith B, et al. PI3kalpha and STAT1 interplay regulates human mesenchymal stem cell immune polarization. Stem Cells. 2015;33(6):1892- 1901.
45. Le Blanc K, Mougiakakos D. Multipotent mesenchymal stromal cells and the innate immune system. Nat. Rev. Immunol. 2012;12(5):383-396.
46. Kim SJ, Shan P, Hwangbo C, et al. Endothelial toll-like receptor 4 maintains lung integrity via epigenetic suppression of p16(INK4a). Aging Cell. 2019:e12914.
47. Hoermann G, Cerny-Reiterer S, Herrmann H, et al. Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neo- plasms. FASEB J. 2012;26(2):894-906.
48. Li Y, Wang L, Pappan L, Galliher-Beckley A, Shi J. IL-1beta promotes stemness and inva- siveness of colon cancer cells through Zeb1 activation. Mol Cancer. 2012;11:87.
49. Suboticki T, Mitrovic Ajtic O, Beleslin- Cokic BB, et al. IL-6 stimulation of DNA replication is JAK1/2 mediated in cross-talk with hyperactivated ERK1/2 signaling. Cell Biol. Int. 2019;43(2):192-206.
50. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006; 8(4):315-317.
haematologica | 2020; 105(3)
673